J.P. Morgan Maintains Overweight Rating on Ariad Pharmaceuticals

According to J.P. Morgan, Ariad Pharmaceuticals

Overweight rating is maintained. J.P. Morgan said that it is attending the 2011 ASH conference in San Diego, where interim data were presented on Sunday afternoon for the pivotal PACE trial evaluating ponatinib in chronic myeloid leukemia (

) patients. “The bottom line is that so far PACE looks as if it is on track to be a successful trial with trends reminiscent of the Ph1 data. Reiterate OW.” Ariad Pharmaceuticals closed on Friday at $11.63.